Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies

Clin Infect Dis. 2005 Sep 15;41(6):901-5. doi: 10.1086/432879. Epub 2005 Aug 15.

Abstract

The effect of therapy with a combination of tenofovir and full-dose didanosine on increases in CD4+ cell count was examined in 2 large trials of treatment-experienced patients with human immunodeficiency virus (HIV) infection (the T-20 versus Optimized Regimen Only [TORO] 1 and 2 clinical trials). Individuals receiving both agents showed little additional increase in CD4+ cell count after week 8 of therapy, whereas those receiving 1 or neither of the agents had continuous increases over a 48-week period.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / analogs & derivatives*
  • Adenine / therapeutic use
  • Anti-HIV Agents / therapeutic use*
  • CD4 Lymphocyte Count
  • Didanosine / therapeutic use*
  • Drug Therapy, Combination
  • Enfuvirtide
  • HIV Envelope Protein gp41 / therapeutic use
  • HIV Infections / drug therapy*
  • HIV Infections / immunology*
  • Humans
  • Organophosphonates / therapeutic use*
  • Peptide Fragments / therapeutic use
  • Tenofovir
  • Time Factors
  • Viral Load

Substances

  • Anti-HIV Agents
  • HIV Envelope Protein gp41
  • Organophosphonates
  • Peptide Fragments
  • Enfuvirtide
  • Tenofovir
  • Adenine
  • Didanosine